Recipharm Invests In Its Single Dose Nasal Platform Capabilities

Recipharm, a global contract development and manufacturing organisation (CDMO), has announced that it is expanding its capabilities for its proprietary Unidose Xtra (single dose) nasal delivery platform.

Offering advantages over standard systemic delivery systems, Recipharm has seen interest in intranasal drug delivery in pharmaceutical R&D increase significantly over the last 10 years. The potential benefits of nasal delivery include offering a more favourable patient experience, with targeted delivery resulting in a faster response to the medication.

Recipharm has already invested in several of its sites in the UK and US to expand its capabilities for the Unidose Xtra delivery platform and the following services are now available:

• Development of Unidose Xtra prototypes
• Filling and assembly capabilities to support pre-clinical evaluations
• System performance testing with regards spray characteristics

The following services using performance-ready components will be offered:

• Full method development
• Formulation and Container Closure System (CCS) screening/characterisation
• GMP material manufacturing and supply
• Development stability testing

A feasibility study package will also be available. Furthermore, Recipharm’s new GMP suite is being built in North Carolina to support clinical manufacturing.

Joe Neale, Head of Innovation, Development and Programme Management at Recipharm said: “Our customers and therefore patients can benefit from Recipharm’s superior product, and we are proud to be creating a benchmark for ‘real world nasal drug delivery performance’. Our ability to offer drug formulation specific tailoring provides a competitive advantage.”